Julian Sevilla

List of Publications by Year
in descending order

111 papers	2,982 citations	159585 30 h-index	197818 49 g-index
127 all docs	127 docs citations	127 times ranked	4144 citing authors

#	Article	IF	Citations
1	Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. New England Journal of Medicine, 2020, 382, 1811-1822.	27.0	320
2	Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematology,the, 2015, 2, e315-e325.	4.6	146
3	Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. Nature Medicine, 2019, 25, 1396-1401.	30.7	117
4	Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood, 2011, 117, 3759-3769.	1.4	108
5	Leukocyte adhesion deficiency-I: A comprehensive review of all published cases. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1418-1420.e10.	3.8	85
6	High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Journal of Neuro-Oncology, 2005, 71, 33-38.	2.9	80
7	Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. Bone Marrow Transplantation, 2004, 33, 675-690.	2.4	71
8	A phase I/II trial of interleukin-15â€“stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy, 2015, 17, 1594-1603.	0.7	69
9	Osmotic gradient ektacytometry: A valuable screening test for hereditary spherocytosis and other red blood cell membrane disorders. International Journal of Laboratory Hematology, 2018, 40, 94-102.	1.3	67
10	KIRâ€“HLA receptorâ€ligand mismatch associated with a graftâ€versusâ€tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatric Blood and Cancer, 2009, 53, 120-124.	1.5	64
11	NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia. Cell Stem Cell, 2019, 25, 607-621.e7.	11.1	64
12	Increasing Incidence of Invasive Aspergillosis in Pediatric Hematology Oncology Patients Over the Last Decade. Journal of Pediatric Hematology/Oncology, 2009, 31, 642-646.	0.6	54
13	Therapeutic gene editing in <scp>CD</scp> 34 ⁺ hematopoietic progenitors from Fanconi anemia patients. EMBO Molecular Medicine, 2017, 9, 1574-1588.	6.9	54
14	Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. British Journal of Haematology, 2018, 183, 110-118.	2.5	53
15	Chromosome fragility in patients with Fanconi anaemia: diagnostic implications and clinical impact. Journal of Medical Genetics, 2011, 48, 242-250.	3.2	51
16	A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. Journal of Medical Genetics, 2007, 44, 241-249.	3.2	47
17	Therapeutic embolization and surgical excision of haemophilic pseudotumour. Haemophilia, 1999, 5, 360-363.	2.1	45
18	Stem Cell Gene Therapy for Fanconi Anemia: Report from the 1st International Fanconi Anemia Gene Therapy Working Group Meeting. Molecular Therapy, 2011, 19, 1193-1198.	8.2	45

#	Article	IF	Citations
19	Lentiviral-mediated Genetic Correction of Hematopoietic and Mesenchymal Progenitor Cells From Fanconi Anemia Patients. Molecular Therapy, 2009, 17, 1083-1092.	8.2	44
20	Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Experimental Hematology, 2012, 40, 882-891.e1.	0.4	43
21	Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients. Blood, 2017, 130, 1535-1542.	1.4	42
22	Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency. Haematologica, 2018, 103, e82-e86.	3.5	42
23	Predicting factors for admission to an intensive care unit and clinical outcome in pediatric patients receiving hematopoietic stem cell transplantation. Haematologica, 2002, 87, 292-8.	3.5	41
24	Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. Bone Marrow Transplantation, 2012, 47, 1419-1427.	2.4	37
25	Transient donor cell-derived myelodysplastic syndrome with monosomy 7 after unrelated cord blood transplantation. European Journal of Haematology, 2006, 77, 259-263.	2.2	34
26	Graft Manipulation and Reduced-intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation From Mismatched Unrelated and Mismatched/Haploidentical Related Donors in Pediatric Leukemia Patients. Journal of Pediatric Hematology/Oncology, 2010, 32, e85-e90.	0.6	34
27	Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors. Leukemia Research, 2017, 57, 60-64.	0.8	33
28	Malignant atrophic papulosis in an infant. British Journal of Dermatology, 2002, 146, 916-918.	1.5	32
29	Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT). Annals of Hematology, 2003, 82, 649-653.	1.8	32
30	Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells. Stem Cell Reports, 2015, 5, 1053-1066.	4.8	32
31	Risk Score for Pediatric Intensive Care Unit Admission in Children Undergoing Hematopoietic Stem Cell Transplantation and Analysis of Predictive Factors for Survival. Journal of Pediatric Hematology/Oncology, 2005, 27, 526-531.	0.6	31
32	Peripheral blood progenitor cell collection adverse events for childhood allogeneic donors: variables related to the collection and safety profile. British Journal of Haematology, 2009, 144, 909-916.	2.5	31
33	Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia. Current Gene Therapy, 2017, 16, 338-348.	2.0	31
34	Granulocyte colony-stimulating factor alone at 12 Î¼g/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. Bone Marrow Transplantation, 2002, 30, 417-420.	2.4	30
35	High-dose Chemotherapy With Autologous Stem Cell Rescue as First Line of Treatment in Young Children with Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumors. Journal of Neuro-Oncology, 2004, 67, 101-106.	2.9	30
36	Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study. European Journal of Haematology, 2011, 87, 46-53.	2.2	29

#	Article	IF	Citations
37	Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts. Bone Marrow Transplantation, 2016, 51, 1211-1216.	2.4	29
38	Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. Annals of Hematology, 2002, 81, 11-15.	1.8	27
39	Engraftment syndrome in children undergoing autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplantation, 2002, 30, 355-358.	2.4	27
40	Acute autoimmune hemolytic anemia following unrelated cord blood transplantation as an early manifestation of chronic graft-versus-host disease. Bone Marrow Transplantation, 2001, 28, 89-92.	2.4	26
41	Extracorporeal photochemotherapy for steroid-refractory graft-versus-host disease in low-weight pediatric patients. Immunomodulatory effects and clinical outcome. Haematologica, 2008, 93, 1278-1280.	3.5	26
42	Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation. Haematologica, 2003, 88, 919-22.	3.5	25
43	Large volume leukapheresis in small children: safety profile and variables affecting peripheral blood progenitor cell collection. Bone Marrow Transplantation, 2003, 31, 263-267.	2.4	24
44	Analysis of Clinical Outcome and Survival in Pediatric Patients Undergoing Extracorporeal Photopheresis for the Treatment of Steroid-refractory GVHD. Journal of Pediatric Hematology/Oncology, 2010, 32, 589-593.	0.6	24
45	Intrathecal liposomal cytarabine in children under 4Âyears with malignant brain tumors. Journal of Neuro-Oncology, 2009, 95, 65-69.	2.9	22
46	Fatal Hepatic Failure Secondary to Acute Herpes Simplex Virus Infection. Journal of Pediatric Hematology/Oncology, 2004, 26, 686-688.	0.6	21
47	Priming of Hematopoietic Progenitor Cells by Plerixafor and Filgrastim in Children With Previous Failure of Mobilization With Chemotherapy and/or Cytokine Treatment. Journal of Pediatric Hematology/Oncology, 2012, 34, 146-150.	0.6	21
48	High resolution melting analysis for the identification of novel mutations in DKC1 and TERT genes in patients with dyskeratosis congenita. Blood Cells, Molecules, and Diseases, 2012, 49, 140-146.	1.4	21
49	Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes. Orphanet Journal of Rare Diseases, 2019, 14, 82.	2.7	21
50	Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome. Bone Marrow Transplantation, 2004, 34, 1051-1055.	2.4	20
51	Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis. Transplant Infectious Disease, 2008, 10, 193-196.	1.7	19
52	Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency. PLoS ONE, 2019, 14, e0216674.	2.5	19
53	A Simplified Approach to Improve the Efficiency and Safety ofEx VivoHematopoietic Gene Therapy in Fanconi Anemia Patients. Human Gene Therapy, 2006, 17, 245-250.	2.7	18
54	Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia. Blood Advances, 2017, 1, 319-329.	5.2	18

#	Article	IF	Citations
55	Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. Journal of Medical Genetics, 2020, 57, 258-268.	3.2	18
56	Autologous peripheral blood stem cell transplant in patients previously diagnosed with invasive aspergillosis. Annals of Hematology, 2001, 80, 456-459.	1.8	17
57	Engraftment Syndrome Emerges as the Main Cause of Transplant-Related Mortality in Pediatric Patients Receiving Autologous Peripheral Blood Progenitor Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2004, 26, 492-496.	0.6	15
58	A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplantation, 2004, 34, 1077-1081.	2.4	14
59	Risks and methods for peripheral blood progenitor cell collection in small children. Transfusion and Apheresis Science, 2004, 31, 221-231.	1.0	14
60	HIGH-DOSE BUSULFAN AND MELPHALAN AS CONDITIONING REGIMEN FOR AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION IN HIGH-RISK EWING SARCOMA PATIENTS: A Long-Term Follow-Up Single-Center Study. Pediatric Hematology and Oncology, 2010, 27, 272-282.	0.8	14
61	Defining â€œpoor mobilizerâ€• in pediatric patients who need an autologous peripheral blood progenitor cell transplantation. Cytotherapy, 2013, 15, 132-137.	0.7	14
62	Haploâ€•identical or mismatched unrelated donor hematopoietic cell transplantation for <scp>Fanconi</scp> anemia: Results from the <scp>Severe Aplastic Anemia Working Party</scp> of the <scp>EBMT</scp>. American Journal of Hematology, 2021, 96, 571-579.	4.1	14
63	Successful Treatment of Trichosporon beigelii Pneumonia with Itraconazole. Clinical Infectious Diseases, 1998, 26, 999-1000.	5.8	13
64	Peripheral Blood Progenitor Cell Collection in Low-Weight Children. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 633-642.	1.8	13
65	Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using Î±Î²+ T-Cell Receptor and CD19+ Cell Depleted Grafts: High CD56dim/CD56bright NK Cell Ratio Early Following Transplantation Is Associated With Lower Relapse Incidence and Better Outcome. Frontiers in Immunology, 2019, 10, 2504.	4.8	13
66	Natural gene therapy by reverse mosaicism leads to improved hematology in <scp>Fanconi</scp> anemia patients. American Journal of Hematology, 2021, 96, 989-999.	4.1	13
67	Chemotherapy-Related Secondary Acute Myeloid Leukemia in Patients Diagnosed With Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2004, 26, 454-456.	0.6	12
68	ALLOGENEIC CORD BLOOD TRANSPLANTATION IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES: A Long-Term Follow-Up Single-Center Study. Pediatric Hematology and Oncology, 2009, 26, 165-174.	0.8	12
69	Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC). Bone Marrow Transplantation, 2020, 55, 1744-1753.	2.4	12
70	Hematopoietic transplantation for bone marrow failure syndromes and thalassemia. Bone Marrow Transplantation, 2005, 35, S17-S21.	2.4	11
71	PBSC collection in extremely low weight infants: a single-center experience. Cytotherapy, 2007, 9, 356-361.	0.7	11
72	Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLAâ€•matched allogeneic stem cell transplantation in childhood leukaemia patients. British Journal of Haematology, 2008, 140, 340-343.	2.5	10

#	Article	IF	Citations
73	DÃ©ficit de piruvato cinasa eritrocitaria en EspaÃ±a: estudio de 15 casos. Medicina ClÃnica, 2017, 148, 23-27.	0.6	10
74	Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Molecular Therapy - Methods and Clinical Development, 2021, 22, 66-75.	4.1	10
75	Severe systemic autoimmune disease associated with Epstein-Barr virus infection. Journal of Pediatric Hematology/Oncology, 2004, 26, 831-3.	0.6	6
76	Early onset of acute immune-mediated lung injury in a child undergoing allogeneic peripheral blood transplantation. American Journal of Hematology, 2002, 69, 56-58.	4.1	5
77	Successful Treatment of Invasive Aspergillosis With Oral Voriconazole Following Intravenous Liposomal Amphotericin in a Child With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2004, 26, 117-119.	0.6	5
78	Pyruvate kinase deficiency and severe congenital hemolytic anemia in a double heterozygous patient with paternal transmission of an early germâ€line de novo mutation. American Journal of Hematology, 2015, 90, E217-9.	4.1	5
79	Clinical and economic evaluation of using granulocyte colony-stimulating factor after autologous peripheral blood progenitor cell transplantation in children. Haematologica, 2002, 87, 105-6.	3.5	5
80	Dyspnea as the first manifestation of primary pancreatic lymphoma. Pediatric Blood and Cancer, 2008, 50, 434-434.	1.5	4
81	Compassionate Use Study of Caspofungin in Children with Proven or Suspected Invasive Mycosis or Persistent Febrile Neutropenia. Journal of Chemotherapy, 2009, 21, 229-231.	1.5	4
82	Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients. Blood, 2021, 138, 563-563.	1.4	4
83	Early Acute Myeloblastic Leukemia Treatment for Childhood Myelodysplastic Syndrome With t(3;5) (NPM/MLF1). Journal of Pediatric Hematology/Oncology, 2007, 29, 839-840.	0.6	3
84	Pulmonary Glial Heterotopia in a Child Diagnosed With Fanconi Anemia and Epilepsy. Journal of Pediatric Hematology/Oncology, 2011, 33, 462-464.	0.6	3
85	Hb Cibeles [Î±2 CD25(B6) (GlyÂâ†'ÂAsp)]: a novel alpha chain variant causing alpha-thalassemia. International Journal of Hematology, 2014, 100, 599-601.	1.6	3
86	Plerixaforâ€based mobilization in pediatric healthy donors with unfavorable donor/recipient body weight ratio resulted in a better <scp>CD34</scp>⁺ collection yield: A retrospective analysis. Journal of Clinical Apheresis, 2021, 36, 78-86.	1.3	3
87	Variables related to chronic immune thrombocytopenia: experience from a single center and comparison to a meta-analysis. European Journal of Pediatrics, 2021, 180, 2075-2081.	2.7	3
88	Graft failure after â€œex-vivoâ€•T-cell depleted haploidentical transplantation in pediatric patients with high-risk hematological malignancies. A risk factors and outcomes analysis. Leukemia and Lymphoma, 2021, 62, 1-8.	1.3	3
89	Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (<scp>PKD</scp>)?: Toward an expanded definition of severe <scp>PKD</scp>. American Journal of Hematology, 2022, 97, .	4.1	3
90	Varicella zoster central nervous system vasculitis after allogeneic hematopoietic stem cell transplant successfully treated with cyclophosphamide. Transplant Infectious Disease, 2012, 14, E107-10.	1.7	2

#	Article	IF	Citations
91	Using Rheopheresis for stem cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). Transfusion and Apheresis Science, 2013, 49, 234-237.	1.0	2
92	IgAâ€Mediated Autoimmune Hemolytic Anemia: A Clinical Conundrum. Pediatric Blood and Cancer, 2016, 63, 754-754.	1.5	2
93	Anemias raras y fallos medulares hereditarios. Arbor, 2018, 194, 463.	0.3	2
94	A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline. Leukemia, 2021, 35, 3295-3298.	7.2	2
95	Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia. Journal of Clinical Investigation, 2022, 132, .	8.2	2
96	Hemiparesis in an Adolescent With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2016, 38, 63-64.	0.6	1
97	Leucemia aguda en pacientes con sÃndrome de Down. Anales De PediatrÃa, 2004, 61, 515-519.	0.2	1
98	Immunomagnetic T Cell Depletion: an Analysis of Variables Affecting Final Cell Yield. Clinical Laboratory, 2016, 62, 1243-1248.	0.5	1
99	Mobilization with highâ€dose granulocyte colonyâ€stimulating factor alone at 12â€‰Î¼g/kg twice a day in highâ€risk pediatric patients: A retrospective analysis of the experience in a single center. Journal of Clinical Apheresis, 2022, 37, 420-429.	1.3	1
100	Trasplante autÃ³logo con progenitores hematopoyÃ©ticos de sangre perifÃ©rica en niÃ±os con tumores del sistema nervioso central de alto riesgo. Anales De PediatrÃa, 2004, 61, 8-15.	0.2	1
101	T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCRÎ±Î²+/CD19+ Depletion Platforms. Frontiers in Oncology, 0, 12, .	2.8	1
102	Extramedullary acute lymphoblastic leukaemia in childhood. European Journal of Haematology, 2007, 79, 182-182.	2.2	0
103	AfÃ©resis en PediatrÃa. Anales De Pediatria Continuada, 2014, 12, 256-259.	0.1	0
104	Outcome and Prognostic Factors for Pediatric Patients Receiving an Haploidentical Transplantation Using CD3/CD19 Depleted Grafts. Biology of Blood and Marrow Transplantation, 2014, 20, S33.	2.0	0
105	Protocolo diagnÃ³stico y tratamiento de la anemia microcÃtica en el adolescente. Medicine, 2018, 12, 3613-3618.	0.0	0
106	Vox Sanguinis International Forum on paediatric indications for blood component transfusion. Vox Sanguinis, 2019, 114, e36-e90.	1.5	0
107	Management of primary immune thrombocytopenia. A comparison between two historical cohorts. Anales De PediatrÃa (English Edition), 2021, 95, 86-92.	0.2	0
108	DiagnÃ³stico y tratamiento de la trombocitemia esencial en la edad pediÃ¡trica. , 2013, , 27-33.		0

#	Article	IF	Citations
109	NHEJ-Mediated Gene Editing: An Efficient Approach to Correct Mutations in Hematopoietic Stem and Progenitor Cells from Patients with Fanconi Anemia. SSRN Electronic Journal, 0, , .	0.4	0
110	Letter to the Editor: Hematopoietic Stem and Progenitor Cell Mobilization and Collection for Patients Diagnosed with Osteopetrosis and Hurler Syndrome. Human Gene Therapy, 2022, 33, 213-214.	2.7	0
111	Hemoptisis fatal secundaria a aspergilosis pulmonar invasiva en una paciente con leucemia mieloblÃ¡stica aguda. Anales De PediatrÃa, 2007, 67, 278-279.	0.2	0